Clinical trials: Diabetes Type 2
Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
This is a phase III, randomized, double-blind, multicenter, parallel group, repeat-dose, study of 26 weeks duration to evaluate the efficacy, safety, tolerability and pharmacodynamic response of albiglutide liquid drug product…
- Trial name
- NCT02683746
- Testing
- Lyophilized albiglutide DCC pen injector, Albiglutide liquid auto-injector
- Where
- 70 sites in United States
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of LY2189102 in Patients With Type 2 Diabetes
Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.
- Trial name
- NCT00942188
- Testing
- LY2189102
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
DIabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252694)
- Testing
- candesartan
- Volunteers
- 4,717 people
- Sponsor
- AstraZeneca
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
Impact of Breakfast Composition on Glycemic and Incretin Responses in Individuals With Type 2 Diabetes
This study examined the effect of a high protein or high carbohydrate breakfast on the glucose and insulin response following the breakfast meal, as well as the subsequent response following the lunch meal.
- Trial name
- NCT02180646
- Testing
- High protein breakfast, High carb breakfast
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or…
- Trial name
- NCT01232946
- Testing
- liraglutide, insulin detemir, liraglutide plus insulin detemir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Diabetes Mellitus, Non-Insulin-Dependent
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00758069
- Testing
- sitagliptin phosphate, Comparator: Sitagliptin
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy
Clinic to Community Connections - Broader Distribution
This study addresses education needs in gestational diabetes care and followup at the staff and patient levels. In the initial phase, nurses and community health workers will complete specific training modules on gestational…
- Trial name
- NCT04474795
- Testing
- Staff -Educational training
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes
Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes
The goal of this clinical trial is to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes.
- Trial name
- NCT05683392
- Testing
- t:slim X2 insulin pump with Control-IQ technology 2.0
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes
Point-of-Care Glucose Testing and Insulin Supplementation
Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting.
- Trial name
- POC (NCT01702311)
- Testing
- Bedtime insulin Aspart (Novolog)
- Where
- 2 sites in United States
- Volunteers
- 235 people
- Sponsor
- Emory University
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes
For the nearly 75% of patients living with type 2 diabetes (T2DM) that do not use insulin, decisions regarding self-monitoring of blood glucose (SMBG) are unclear.
- Trial name
- NCT02033499
- Testing
- SMBG
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes, Food Insecurity
Changing Health Through Food Support for Diabetes
This is a pragmatic randomized controlled trial (RCT) of Changing Health through Food Support for Diabetes (CHEFS-DM). This pragmatic RCT will leverage Project Open Hand's (POH) real-world programs to test the impact of a six…
- Trial name
- CHEFS-DM (NCT04959487)
- Testing
- Food support, Nutritional Counseling and education
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- University of California, San Francisco
Type 2 Diabetes Mellitus
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"
To investigate the safety and efficacy of long-term treatment with pioglitazone (Actos tablets) in combination with biguanides (for 12 months after the start of pioglitazone tablets treatment) in patients with type 2 diabetes…
- Trial name
- NCT02003014
- Testing
- Pioglitazone
- Volunteers
- 899 people
- Sponsor
- Takeda
Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese
Implementation of a Peer Leader-facilitated Dyadic Intervention
This Pilot Study Large Application builds upon the results of our prior work to 1) Implement and pilot test a peer leader-facilitated 12-week dyadic intervention (Community Health among Asian Indian immigrants (CHAI) Dyad study)…
- Conditions
- Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese, Hyperlipidemias
- Trial name
- NCT06643806
- Testing
- CHAI dyad study
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Diabetes, Executive Dysfunction
Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)
Diabetes increases the risk of cognitive dysfunction. The incidence of dementia is 1.5 to 2.5 times higher in persons with diabetes than the general population.
- Trial name
- THINK-D (NCT02416193)
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Loyola University
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)
This study aims to randomly assign individuals with type 2 diabetes into the ENHANCED randomized control trial. The study is being conducted by the Minneapolis Heart Institute Foundation (MHIF) and will have two study sites 1)…
- Trial name
- ENHANCED (NCT02980978)
- Testing
- Coaching
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Minneapolis Heart Institute Foundation
Diabetes Mellitus, Type 2
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
- Trial name
- NCT03817463
- Testing
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Where
- 13 sites in Denmark, Finland and 9 more
- Volunteers
- 327,624 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.